Originality and innovation are watchwords for one of Europe’s newest cancer research funders
- Lymph&Co particularly appreciates interdisciplinary applications
- Lead applicants should have a strong publication record in lymphoma research or be able to demonstrate their expertise in the field in another way
- The charity welcomes fundamental, translational and clinical research bids
- Innovation is highly prized but where there is little precedent in the literature, preliminary data should be included
The charity Lymph&Co was formed in 2016 with much of the initial impetus coming from one of its co-founders, the Dutch royal family member Bernhard van Oranje. After recovering from lymphoma, van Oranje learnt that there was no dedicated Dutch fund for lymphoma research and set to work.